Sinthujan Jegaskanda1, Catherine Luke2, Heather D Hickman3, Mark Y Sangster4, Wendy F Wieland-Alter5, Jacqueline M McBride6, Jon W Yewdell3, Peter F Wright5, John Treanor4, Carrie M Rosenberger7, Kanta Subbarao2. 1. Laboratory of Infectious Diseases Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, Melbourne, Australia. 2. Laboratory of Infectious Diseases. 3. Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland. 4. Department of Medicine, University of Rochester Medical Center, New York. 5. Department of Pediatrics, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire. 6. Biomarker Development. 7. Biomarker Discovery, Genentech, South San Francisco, California.
Abstract
BACKGROUND: Nonneutralizing antibodies (Abs) involved in antibody-dependent cellular cytotoxicity (ADCC) may provide some protection from influenza virus infection. The ability of influenza vaccines to induce ADCC-mediating Abs (ADCC-Abs) in adults and children is unclear. METHODS: We quantified ADCC-Abs in serum samples from adults who received a dose of inactivated subunit vaccine (ISV) targeting monovalent 2009 pandemic influenza A(H1N1) virus or live-attenuated influenza vaccine (LAIV) or who had laboratory-confirmed influenza A(H1N1) virus infection. We also measured ADCC-Abs in children who either received a dose of trivalent seasonal ISV followed by trivalent seasonal LAIV or 2 doses of LAIV. Finally, we assessed the ability of low and high ADCC-Ab titers to protect adults from experimental challenge with influenza A/Wisconsin/67/131/2005(H3N2) virus. RESULTS: Adults and children who received a dose of ISV had a robust increase in ADCC-Ab titers to both recombinant hemagglutinin (rHA) protein and homologous virus-infected cells. There was no detectable increase in titers of ADCC-Abs to rHA or virus-infected cells in adults and children who received LAIV. Higher titers (≥320) of preexisting ADCC-Abs were associated with lower virus replication and a significant reduction in total symptom scores in experimentally infected adults. CONCLUSIONS: ADCC-Ab titers increased following experimental influenza virus infection in adults and after ISV administration in both children and adults. Published by Oxford University Press for the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.
BACKGROUND: Nonneutralizing antibodies (Abs) involved in antibody-dependent cellular cytotoxicity (ADCC) may provide some protection from influenza virus infection. The ability of influenza vaccines to induce ADCC-mediating Abs (ADCC-Abs) in adults and children is unclear. METHODS: We quantified ADCC-Abs in serum samples from adults who received a dose of inactivated subunit vaccine (ISV) targeting monovalent 2009 pandemic influenza A(H1N1) virus or live-attenuated influenza vaccine (LAIV) or who had laboratory-confirmed influenza A(H1N1) virus infection. We also measured ADCC-Abs in children who either received a dose of trivalent seasonal ISV followed by trivalent seasonal LAIV or 2 doses of LAIV. Finally, we assessed the ability of low and high ADCC-Ab titers to protect adults from experimental challenge with influenza A/Wisconsin/67/131/2005(H3N2) virus. RESULTS: Adults and children who received a dose of ISV had a robust increase in ADCC-Ab titers to both recombinant hemagglutinin (rHA) protein and homologous virus-infected cells. There was no detectable increase in titers of ADCC-Abs to rHA or virus-infected cells in adults and children who received LAIV. Higher titers (≥320) of preexisting ADCC-Abs were associated with lower virus replication and a significant reduction in total symptom scores in experimentally infected adults. CONCLUSIONS: ADCC-Ab titers increased following experimental influenza virus infection in adults and after ISV administration in both children and adults. Published by Oxford University Press for the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Authors: Mary Dawn T Co; Masanori Terajima; Stephen J Thomas; Richard G Jarman; Kamonthip Rungrojcharoenkit; Stefan Fernandez; In-Kyu Yoon; Darunee Buddhari; John Cruz; Francis A Ennis Journal: Viral Immunol Date: 2014-08-20 Impact factor: 2.257
Authors: Sinthujan Jegaskanda; Emma R Job; Marit Kramski; Karen Laurie; Gamze Isitman; Robert de Rose; Wendy R Winnall; Ivan Stratov; Andrew G Brooks; Patrick C Reading; Stephen J Kent Journal: J Immunol Date: 2013-01-14 Impact factor: 5.422
Authors: Brian R Long; Jakob Michaelsson; Christopher P Loo; Wassim M Ballan; Bien-Aimee N Vu; Frederick M Hecht; Lewis L Lanier; Joan M Chapman; Douglas F Nixon Journal: Clin Vaccine Immunol Date: 2007-11-14
Authors: Sinthujan Jegaskanda; Karen L Laurie; Thakshila H Amarasena; Wendy R Winnall; Marit Kramski; Robert De Rose; Ian G Barr; Andrew G Brooks; Patrick C Reading; Stephen J Kent Journal: J Infect Dis Date: 2013-06-28 Impact factor: 5.226
Authors: Timothy D Carroll; Sinthujan Jegaskanda; Shannon R Matzinger; Linda Fritts; Michael B McChesney; Stephen J Kent; Jeffery Fairman; Christopher J Miller Journal: J Infect Dis Date: 2018-08-14 Impact factor: 5.226
Authors: Jacqueline M McBride; Jeremy J Lim; Tracy Burgess; Rong Deng; Michael A Derby; Mauricio Maia; Priscilla Horn; Omer Siddiqui; Daniel Sheinson; Haiyin Chen-Harris; Elizabeth M Newton; Dimitri Fillos; Denise Nazzal; Carrie M Rosenberger; Maikke B Ohlson; Rob Lambkin-Williams; Hosnieh Fathi; Jeffrey M Harris; Jorge A Tavel Journal: Antimicrob Agents Chemother Date: 2017-10-24 Impact factor: 5.191
Authors: Sinthujan Jegaskanda; Hillary A Vanderven; Adam K Wheatley; Stephen J Kent Journal: Hum Vaccin Immunother Date: 2017-03-23 Impact factor: 3.452
Authors: Sinthujan Jegaskanda; Mary Dawn T Co; John Cruz; Kanta Subbarao; Francis A Ennis; Masanori Terajima Journal: J Infect Dis Date: 2017-03-01 Impact factor: 5.226
Authors: Elizabeth J Fay; Stephanie L Aron; Ian A Stone; Barbara M Waring; Richard K Plemper; Ryan A Langlois Journal: J Virol Date: 2018-12-10 Impact factor: 5.103